Blueprint Medicines Corporation (NASDAQ:BPMC) Director Daniel Lynch sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $63.38, for a total value of $316,900.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.
Daniel Lynch also recently made the following trade(s):
- On Monday, September 18th, Daniel Lynch sold 2,500 shares of Blueprint Medicines Corporation stock. The stock was sold at an average price of $60.00, for a total value of $150,000.00.
Blueprint Medicines Corporation (NASDAQ:BPMC) traded down $0.57 during midday trading on Friday, hitting $66.17. The stock had a trading volume of 281,027 shares, compared to its average volume of 430,742. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.02. Blueprint Medicines Corporation has a 52 week low of $25.08 and a 52 week high of $74.42.
Blueprint Medicines Corporation (NASDAQ:BPMC) last released its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.96) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.06). The business had revenue of $8.07 million for the quarter, compared to analyst estimates of $5.35 million. Blueprint Medicines Corporation had a negative return on equity of 43.11% and a negative net margin of 437.83%. The company’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.62) EPS. research analysts anticipate that Blueprint Medicines Corporation will post -3.74 earnings per share for the current fiscal year.
A number of equities analysts have issued reports on BPMC shares. Morgan Stanley raised their target price on Blueprint Medicines Corporation from $45.00 to $78.00 and gave the stock an “overweight” rating in a report on Monday, October 23rd. Jefferies Group LLC restated a “buy” rating and set a $56.00 target price on shares of Blueprint Medicines Corporation in a report on Tuesday, September 5th. Zacks Investment Research upgraded Blueprint Medicines Corporation from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Canaccord Genuity restated a “buy” rating and set a $56.00 target price on shares of Blueprint Medicines Corporation in a report on Monday, September 11th. Finally, Goldman Sachs Group, Inc. (The) restated a “buy” rating and set a $79.00 target price (up previously from $64.00) on shares of Blueprint Medicines Corporation in a report on Wednesday, September 20th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. Blueprint Medicines Corporation currently has an average rating of “Buy” and a consensus target price of $70.47.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in BPMC. Rockefeller Financial Services Inc. acquired a new stake in shares of Blueprint Medicines Corporation during the third quarter worth about $160,000. Ameritas Investment Partners Inc. raised its position in shares of Blueprint Medicines Corporation by 68.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 1,391 shares during the period. UBS Asset Management Americas Inc. acquired a new stake in shares of Blueprint Medicines Corporation during the first quarter worth about $201,000. Fred Alger Management Inc. acquired a new stake in shares of Blueprint Medicines Corporation during the second quarter worth about $203,000. Finally, SG Americas Securities LLC raised its position in shares of Blueprint Medicines Corporation by 23.3% during the second quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 778 shares during the period. 90.83% of the stock is currently owned by institutional investors.
Blueprint Medicines Corporation Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.